Beijing Kawin Technology Share-Holding (688687) Stock Overview
A biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
688687 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Beijing Kawin Technology Share-Holding Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥19.76 |
| 52 Week High | CN¥40.19 |
| 52 Week Low | CN¥18.81 |
| Beta | 0.74 |
| 1 Month Change | -1.45% |
| 3 Month Change | -10.06% |
| 1 Year Change | -25.74% |
| 3 Year Change | -28.92% |
| 5 Year Change | -42.47% |
| Change since IPO | -52.95% |
Recent News & Updates
Recent updates
Impressive Earnings May Not Tell The Whole Story For Beijing Kawin Technology Share-Holding (SHSE:688687)
Oct 28
Why Investors Shouldn't Be Surprised By Beijing Kawin Technology Share-Holding Co., Ltd.'s (SHSE:688687) 36% Share Price Surge
Oct 01We Think Beijing Kawin Technology Share-Holding (SHSE:688687) Can Stay On Top Of Its Debt
May 06Beijing Kawin Technology Share-Holding Co., Ltd. (SHSE:688687) Stocks Shoot Up 25% But Its P/E Still Looks Reasonable
Mar 14Shareholder Returns
| 688687 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.8% | -4.0% | -0.4% |
| 1Y | -25.7% | 1.1% | 35.5% |
Return vs Industry: 688687 underperformed the CN Biotechs industry which returned 1.1% over the past year.
Return vs Market: 688687 underperformed the CN Market which returned 35.5% over the past year.
Price Volatility
| 688687 volatility | |
|---|---|
| 688687 Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in CN Market | 9.8% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 688687 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688687's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 600 | Desheng Zhou | www.kawin.com.cn |
Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhizin tablets, capsules, and injections; and pirfenidone tablets for mild to moderate idiopathic pulmonary fibrosis. It is also involved in contract manufacture organization/contract development and manufacturing organization; technology and biotechnology development; technical consulting; biotechnology consulting; science and technology promotion and application; and wholesale of medical supplies.
Beijing Kawin Technology Share-Holding Co., Ltd. Fundamentals Summary
| 688687 fundamental statistics | |
|---|---|
| Market cap | CN¥3.36b |
| Earnings (TTM) | CN¥11.06m |
| Revenue (TTM) | CN¥1.30b |
Is 688687 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688687 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.30b |
| Cost of Revenue | CN¥252.13m |
| Gross Profit | CN¥1.04b |
| Other Expenses | CN¥1.03b |
| Earnings | CN¥11.06m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.066 |
| Gross Margin | 80.55% |
| Net Profit Margin | 0.85% |
| Debt/Equity Ratio | 27.7% |
How did 688687 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 15:07 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beijing Kawin Technology Share-Holding Co., Ltd. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Shitong Han | Citic Securities Co., Ltd. |
| Yiling Chen | Guosen Securities Co., Ltd. |